5 Multiple myeloma flow cytometry panel validated for clinical monitoring of patients

by Bevan Gang, Vicky Sgouroudis, Virginia Litwin, Anita Boyapati
Published 2020-11-01

High levels of interleukin-6 in patients with rheumatoid arthritis are associated with greater improvements in health-related quality of life for sarilumab compared with adalimumab

by Vibeke Strand, Susan H. Boklage, Toshio Kimura, Florence Joly, Anita Boyapati, Jérôme Msihid
Published 2020-10-01

Population Pharmacodynamic Model of Neutrophil Margination and Tolerance to Describe Effect of Sarilumab on Absolute Neutrophil Count in Patients with Rheumatoid Arthritis

by Pavel Kovalenko, Anne Paccaly, Anita Boyapati, Christine Xu, Gregory St John, Michael C. Nivens, John D. Davis, Ronda Rippley, A. Thomas DiCioccio
Published 2020-07-01

Sarilumab and adalimumab differential effects on bone remodelling and cardiovascular risk biomarkers, and predictions of treatment outcomes

by Cem Gabay, Gerd R. Burmester, Vibeke Strand, Jérôme Msihid, Moshe Zilberstein, Toshio Kimura, Hubert van Hoogstraten, Susan H. Boklage, Jonathan Sadeh, Neil M. H. Graham, Anita Boyapati
Published 2020-04-01